Company Overview

Verona Pharma plc is a biopharmaceutical company focused on developing and commercializing therapies for the treatment of respiratory diseases with unmet medical needs. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. Verona Pharma trades on Nasdaq under the ticker VRNA.

Core Product - Ohtuvayre

Verona Pharma's flagship product is Ohtuvayre (ensifentrine), a dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease (COPD), as well as cystic fibrosis and asthma. Ohtuvayre represents the first novel inhaled therapy available for the maintenance treatment of COPD in over 20 years.

The drug addresses a significant market opportunity, as COPD affects approximately 16 million Americans and 600 million people worldwide. The company recently received FDA approval for its inhaled non-steroidal COPD treatment, Ohtuvayre.

Financial Performance - Q1 2025

Revenue Growth

Verona Pharma reported total net revenue of $76.3 million for Q1 2025, driven by Ohtuvayre net sales of $71.3 million, representing a 95% increase versus Q4 2024. The company filled approximately 25,000 prescriptions for Ohtuvayre in Q1 2025, with new patient starts up over 25% compared to Q4 2024.

Financial Position

As of March 31, 2025, Verona Pharma had cash and cash equivalents of $401.4 million. For the first time, the company's quarterly revenue exceeded its operating expenses, excluding non-cash charges. The company reported a net loss of $16.3 million for Q1 2025.

Market Capitalization

As of September 15, 2025, Verona Pharma stock closed at $106.37 per share, with a market capitalization of $9.039 billion.

Operational Highlights

Commercial Success

More prescriptions were dispensed through February 2025 than in the entire fourth quarter of 2024, with more than 4,600 unique healthcare professionals, including approximately 55% of Tier 1 HCPs, having prescribed Ohtuvayre. Ohtuvayre is being prescribed for maintenance therapy across a broad COPD population, including those receiving background single, dual, and approximately 50% on triple therapy.

International Expansion

In February 2025, Verona's development partner in Greater China, Nuance Pharma, announced Ohtuvayre has been approved in Macau for the maintenance treatment of COPD in adult patients, marking the first regulatory approval for Ohtuvayre outside of the US.

Patent Protection

A newly granted patent (US Patent No. 12,251,384), expiring June 2044, was listed in the FDA's Orange Book for Ohtuvayre, in addition to the three original Orange Book listed patents.

Future Growth Initiatives

Sales Expansion

Verona Pharma plans to expand its sales force by adding about 30 new sales representatives in Q3 2025 to further accelerate Ohtuvayre's launch.

Regulatory Progress

The company is progressing regulatory activities for potential marketing authorization application submissions for Ohtuvayre for the maintenance treatment of COPD in the European Union and the UK in 2025.

Clinical Development

In the second quarter of 2025, the Company's development partner in Greater China, Nuance Pharma, is expected to report results from its pivotal Phase 3 trial evaluating ensifentrine for the maintenance treatment of COPD in China. The Company plans to start a dose-ranging Phase 2b trial to assess the safety and efficacy of a fixed-dose nebulized combination of ensifentrine with glycopyrrolate in the second half of 2025, and continues to enroll subjects in a Phase 2 trial to assess the efficacy and safety of nebulized ensifentrine in patients with bronchiectasis.

Strategic Financing

In March 2025, Verona amended its strategic financing agreements by repaying the revenue interest purchase and sales agreement and increasing the debt facility to $450 million under more favorable terms with funds managed by Oaktree Capital and OMERS Life Sciences. At March 31, 2025, the Company had $250 million outstanding under this facility and $200 million available in potential future draws.

Recent Corporate Development

Merck has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup as it braces for the 2028 loss of patent exclusivity for the blockbuster cancer drug Keytruda. The deal is expected to close in the fourth quarter of 2025.

Verona Pharma represents a compelling investment opportunity in the respiratory therapeutics space, with strong commercial traction for its innovative COPD treatment and significant growth potential through geographic expansion and pipeline development.